Skip to content

A randomised placebo-controlled trial of rivastigmine in delirium in older medical in-patients: a pilot study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN27327721
Enrollment
50
Registered
2005-10-28
Start date
2004-04-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium Signs and Symptoms Delirium, not induced by alcohol and other psychoactive substances

Interventions

Rivastigmine up to 1.5 mg twice a day or placebo.

Sponsors

South Manchester University Hospitals NHS Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients over 65 years old 2. Admitted to elderly acute medical ward or orthopaedic ward 3. Patient has a delirium as measured on the Confusion Assessment Method or doesn't have a delirium and has a fractured neck of femur caused by trauma

Exclusion criteria

Exclusion criteria: 1. Patient already on cholinesterase inhibitor 2. Patient has had a previous adverse reaction to a cholinesterase inhibitor 3. If considered by medical team in charge of care to be in the terminal phase of illness 4. Acute chronic obstructive pulmonary disease (COPD) or asthma 5. Has a dysrhythmia on electrocardiogram (ECG) 6. Urea >20 or creatinine >200

Design outcomes

Primary

MeasureTime frame
1. If develops delirium as found on Confusion Assessment Method 2. Length of delirium, measured in days

Secondary

MeasureTime frame
1. Length of admission 2. Change in mini-mental state examination score 3. Use of other psychotropic medication during treatment e.g. benzodiazepines

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026